Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jun 15, 2024; 15(6): 1086-1090
Published online Jun 15, 2024. doi: 10.4239/wjd.v15.i6.1086
New perspectives in the management of diabetic nephropathy
Anna Psyllaki, Konstantinos Tziomalos
Anna Psyllaki, Konstantinos Tziomalos, The First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki 54636, Greece
Author contributions: Psyllaki A drafted the manuscript; Tziomalos K critically revised the draft.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Konstantinos Tziomalos, MD, MSc, PhD, Associate Professor, The First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 1 Stilponos Kyriakidi Street, Thessaloniki 54636, Greece. ktziomalos@yahoo.com
Received: January 7, 2024
Revised: February 1, 2024
Accepted: March 25, 2024
Published online: June 15, 2024
Processing time: 156 Days and 6.4 Hours
Core Tip

Core Tip: The management of diabetic nephropathy evolved substantially in recent years with the accumulation of evidence showing that sodium-glucose cotransporter 2 inhibitors and potentially finerenone prevent both renal function deterioration and cardiovascular events.